PROTAGONIST THERAPEUTICS INC (PTGX)
Health Care · Biotechnology · NASDAQ
Protagonist Therapeutics is a biopharmaceutical company developing novel peptide-based therapies to treat chronic diseases through internal research and strategic collaborations.
What PROTAGONIST THERAPEUTICS INC does
Protagonist Therapeutics is a biopharmaceutical company focused on the discovery and development of novel peptide-based drugs. The company utilizes a proprietary technology platform to create targeted therapies that address significant unmet medical needs, primarily through oral and injectable formulations.
Themes: biotechnology, peptide therapeutics, drug discovery, clinical stage biopharma
Fundamentals
- Price$154.32 as of 2026-08-21 close
- Market cap$10.0B as of 2026-08-21
- 1-year return+175.4% 2025-08-21 close $56.04 → 2026-08-21 close $154.32
- P/E119.77 as of 2026-08-24
- Net margin+29.4% as of 2026-08-24
- ROE+12.0% as of 2026-08-24
- Debt / equity0.00 as of 2026-08-24
- Revenue growth (YoY)+34.8% as of 2026-08-24
- Beta1.50 as of 2026-08-24
- Last reported earnings2026-08-05 SEC EDGAR Form 8-K (Item 2.02)
How PTGX compares in its sector
- price-to-earnings ratiotop 10% 203 covered Health Care peers, as of 2026-08-24
- net profit margintop 10% 504 covered Health Care peers, as of 2026-08-24
- operating margintop 25% 504 covered Health Care peers, as of 2026-08-24
- return on equitytop 25% 576 covered Health Care peers, as of 2026-08-24
- free cash flow (absolute dollars, latest fiscal year)middle range 493 covered Health Care peers, as of FY2025
Position among covered Health Care companies that report each metric (minimum 5 peers). A relative position within our covered catalog — not a valuation, quality, or investment judgment. A higher percentile is simply a higher value (for P/E, more expensive on earnings — never "better"). Informational only.
Top 10 scores & list membership
PTGX is not currently in any published Top 10 list. Its scores are below.
Long-term score
Not scored for the long-term list: no shareholder return data.
Short-term score
66.6 #28 of 1,704 scored · #11 of 240 in Health Care
Trend 87th: a "golden cross" — its 50-day average is above its 200-day; catalysts 79th: the analyst consensus rating has improved toward "buy" since the prior reading; weakest is volume and participation 41st: trading volume is about normal versus its 30-day average.
Scores as of 21 Aug 2026. Each bar is a percentile: how this company ranked against every company the score ranked, 0–100. A list is a published formula and its output, not a recommendation. Method version 2.
How PROTAGONIST THERAPEUTICS INC looks technically
PROTAGONIST THERAPEUTICS INC (PTGX) is trading 51.2% above its 200-day average, the long-term trend line — a longer-term uptrend. Its 50-day average crossed above its 200-day average about 353 trading days ago — a "golden cross", a bullish long-term signal. A strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control. Momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30). It made a new 20-day high about 5 trading days ago. It is 4.0% below its all-time high.
Trend
8
| Distance from the 200-day | it is trading 51.2% above its 200-day average, the long-term trend line — a longer-term uptrend | +51.2% |
|---|---|---|
| 50-day moving average | its average price over the last 50 trading days — a short-term trend line — is $134.20 | $134.20 |
| 200-day moving average | its average price over the last 200 trading days — the long-term trend line — is $102.07 | $102.07 |
| Swing structure | each recent peak has been higher than the one before it and each dip has been shallower — the pattern chart-watchers call an uptrend, which describes where price has already been and not where it goes next | higher highs and higher lows |
| Last swing turn | its last significant turn was a swing low 22 calendar days ago — the swings before that are what the structure reading is measured on | 22 sessions |
| Wave structure | its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five; the labelling fails if price closes below 130.63. It is one of several labellings that fit, and it describes the swings already printed, not what comes next. The same swings also read as a three-part correction in leg C. | possible upward five-wave sequence, in wave 3 (one of several readings) |
| Since the 50/200 cross | its 50-day average crossed above its 200-day average about 353 trading days ago — a "golden cross", a bullish long-term signal | 353 sessions |
| Trend strength (14-day ADX) | a strong uptrend is in place — ADX, a 0–100 trend-strength gauge, is 39, with buyers in control | 38.7 |
Momentum
3
| 14-day RSI | momentum is neutral — its 14-day RSI (a 0–100 momentum gauge) is 63, neither overbought (above 70) nor oversold (below 30) | 63.0 |
|---|---|---|
| Position in its 14-day range | it is trading in the upper half of its 14-day range ($132.26 to $160.81) — its "stochastic" reading is 77 out of 100, where 0 would mean closing exactly at the 14-session low and 100 exactly at the high. This measures WHERE the price sits inside its recent range, which is a different question from the RSI beside it: RSI is a momentum gauge, measuring how FAST the price has been moving, so a stock can drift quietly to the bottom of its range with an ordinary RSI, or fall sharply and still sit in the middle. It has been climbing within that range over the last few sessions. | 77.3 |
| Since the MACD crossed zero | MACD, a trend-momentum gauge, is in positive territory (momentum leaning bullish) | 11 sessions |
Range
12
| 52-week high | its highest closing price over the past year (about 252 trading days) was $160.81 | $160.81 |
|---|---|---|
| From the 52-week high | it is 4.0% below its 52-week high (its highest price of the past year) | -4.0% |
| Above the 52-week low | it is 184.8% above its 52-week low (its lowest price of the past year) | +184.8% |
| Below the 52-week high | it is 4.0% below its highest point of the past year | 4.0% |
| Since a 20-day breakout | it made a new 20-day high about 5 trading days ago | 5 sessions |
| Since a 55-day breakout | it made a new 55-day high about 5 trading days ago | 5 sessions |
| All-time high | its highest closing price on record is $160.81 (set on 2026-08-19) | $160.81 |
| Given back of the 52-week move | over the past year its closes ranged ($54.99 to $158.62), and it has given back only a small part of its rise from last year’s low — 4% of it. Chart-watchers call 61.8%-65% given back the "golden pocket" — for this company that is $91.26 to $94.58. It is watched widely enough that orders cluster there, which is the honest reason it matters; it is not a forecast. | 4.2% |
| From the all-time high | it is 4.0% below its all-time high | -4.0% |
| Nearest price level | it is trading 30.8% above a support level at $106.85 — a price it turned at three times since 2026-04-01, most recently on 2026-05-14. Since 2024-08-21 it has 14 such levels below the current price and 0 above. Levels like these describe where the price has reversed or paused before; they are not a forecast of where it will go. | -30.8% |
| All-time low | its lowest closing price on record is $4.47 (set on 2019-12-03) | $4.47 |
| Above the all-time low | it is 3352.3% above its all-time low | +3,352% |
Volatility
5
| Band width vs its own 6 months | day-to-day price swings are wider than usual versus its own recent 6-month history (wider than about 79% of it) | 79th percentile |
|---|---|---|
| Typical daily range | in a typical session it travels about $5.52 between its high and its low — about 3.6% of its price. That is its "average true range" over the last 14 sessions, which also counts the distance from the previous close, so a day that opens well away from yesterday counts as the large move it was | $5.52 |
| Bollinger bands (20-day, ±2σ) | most of its recent trading has stayed between about $128.25 and $162.84 — the "Bollinger bands", a range drawn two standard deviations either side of its 20-day average price, which widens when the stock gets more volatile and narrows when it settles | $128.25 – $145.54 – $162.84 |
| Typical daily range (% of price) | its price moves about 3.6% in a typical session — about typical for the companies we cover. This is the average gap between a session's high and low over the last 14 sessions, counting overnight moves, expressed against the current price so it can be compared with companies trading at any price | 3.6% |
| Stretch from the 200-day average | it is trading 9.5 daily ranges above its 200-day average price (51.2% above it in plain percentage terms) — a way of asking how far it has stretched from its own average in units of how far it normally moves in a day, so a calm company and a jumpy one can be compared on the same scale | 9.5 daily ranges above its 200-day average |
Volume
1
| Volume vs its 30-day average | trading volume is about normal versus its 30-day average | 0.73× |
|---|
Analyst
2
| Change in the average price target | analysts have raised their average price target by 3.1% since the prior reading | +3.1% |
|---|---|---|
| Change in the consensus rating | the analyst consensus rating is unchanged since the prior reading | unchanged |
Candlestick patterns
2
| Since a bullish engulfing | 5 sessions ago it opened below the previous session's close and finished above that session's open — a "bullish engulfing" pair, where one up day more than undid the down day before it | 5 sessions ago |
|---|---|---|
| Since a bearish engulfing | 8 sessions ago it opened above the previous session's close and finished below that session's open — a "bearish engulfing" pair, where one down day more than undid the up day before it | 8 sessions ago |
Price gaps
3
| Gap at the open | it opened on 2026-08-21 0.9% above the previous session's close — an overnight gap, the part of the move that happened while the market was shut, and had not traded back through that level by the close | +0.9% |
|---|---|---|
| Open gap | it gapped 2.4% above the previous close 9 sessions ago and has not traded back through the level it left behind at 145.87 — an "unfilled gap", which describes a price range no trade has since crossed and is not a forecast that it will be crossed | +2.4% |
| Gap filled | a 2.2% gap up opened on 2026-08-19 has been "filled" 2 sessions ago — price traded back through the level the gap left behind, and it closed again during the very session that opened it | 2 sessions ago |
Price streaks
1
| Closing streak | it closed higher in its latest session, after a session that did not close higher — a single up day rather than a run | 1 session up |
|---|
Relative strength
4
| vs market, 1 month | over the past 1 month this stock beat the market by 9.2 percentage points (the stock gained 11.6% while the market gained 2.3%) | +9.2% |
|---|---|---|
| vs market, 3 months | over the past 3 months this stock beat the market by 48.2 percentage points (the stock gained 51.3% while the market gained 3.1%) | +48.2% |
| vs market, 6 months | over the past 6 months this stock beat the market by 75.4 percentage points (the stock gained 86.5% while the market gained 11.1%) | +75.4% |
| vs market, 12 months | over the past 12 months this stock beat the market by 154.9 percentage points (the stock gained 175.4% while the market gained 20.5%) | +154.9% |
Signal agreement
2
| Bullish technical signals | 6 of the 9 technical signals we can compute for it are currently in a bullish state: a strong uptrend, with buyers in control, a "golden cross" — its 50-day average is above its 200-day, trading above its 200-day average, MACD momentum is positive, outperforming the market over 6 months, trading above the Ichimoku cloud — these describe past price behaviour, not a forecast | 6 of 9 |
|---|---|---|
| Bearish technical signals | 0 of the 9 technical signals we can compute for it are currently in a bearish state — these describe past price behaviour, not a forecast | 0 of 9 |
Trend (Ichimoku cloud)
1
| Vs the Ichimoku cloud | trading 23% above the Ichimoku cloud — a band drawn from where its own highs and lows sat up to 2026-07-16 and projected forward over today's price, the side traders read as an established uptrend, with the band below acting as the level that would have to give way. The band itself is moderate, spanning 5.9% of the share price. | +22.5% |
|---|
Volume-weighted price
2
| Vs this year’s average price paid | the price is 46% above the average price paid so far this year, so the typical buyer over that stretch is showing a gain. That average is $105.61 — a volume-weighted average of daily closes over 155 sessions, not a true tick-by-tick VWAP. | +46.1% |
|---|---|---|
| Vs the average paid since it last reported | the price is 2% above the average price paid since it last reported on 2026-08-05 (its 10-Q), so the typical buyer over that stretch is showing a gain. That average is $151.08 — a volume-weighted average of daily closes over 13 sessions, not a true tick-by-tick VWAP. | +2.1% |
Price levels it has turned at before
PTGX last closed at $154.32 on 2026-08-21. Since 2024-08-21 it has turned at 14 prices below its last close and 0 above; the 3 nearest below are listed, nearest first.
| Level | Side | Distance | Evidence |
|---|---|---|---|
| $106.85 | Support | 30.8% below the last close | turned there three times · 2026-04-01 to 2026-05-14 |
| $96.41 | Support | 37.5% below the last close | turned there four times · 2025-12-15 to 2026-05-19 |
| $93.00 | Support | 39.7% below the last close | turned there twice · 2025-10-10 to 2026-06-02 |
A level is a price this company reversed or paused at more than once — they describe past behaviour, not a forecast of where the price will go.
Wave structure
Its recent swings can be read as a five-part upward sequence — what Elliott-wave chartists call an impulse — now in leg 3 of five.
This labelling fails — stops being a possible reading at all — if it closes below $130.63.
This is one of several labellings that fit the same swings, so treat it as a reading rather than the reading. It was chosen from 2 labellings that survived the rules, counting shorter readings of the same bars.
On past moves of this shape the leg has usually ended somewhere between $148.60 and $159.70 — that is where it has tended to end if the count holds, not a forecast of where the price goes.
Alternate reading: The same swings also read as a three-part correction in leg C, which fails on a close below $130.63.
This labelling was already in place when we began recording count changes on 2026-08-13, so how long it has stood is not something we can say yet.
Read from daily closes as of 2026-08-21.
An Elliott-wave count describes the swings already printed and the level that would disprove it. It is not a forecast, a target, or advice.
Screens: Trading above the 200-day moving average · in a strong, established uptrend (ADX) · Analyst price target recently RAISED · Near the all-time high · beating the market · Stretched far above its 200-day average (6+ daily ranges) | Learn: moving average · golden cross · adx · rsi · breakout · all time high
Based on daily closing prices as of 2026-08-21. Describes past price behavior only — informational, not financial advice.
Analyst consensus
- Consensus ratingStrong Buy (1.23 mean, 1=Strong Buy…5=Strong Sell) — 13 analysts
- Mean price target$170.38 range $149.00 – $225.00; median $169.00
Analyst estimates, as of 2026-08-23. These are third-party analyst opinions and price targets, aggregated — not a recommendation, prediction, or advice from stocks-llm. Informational only.
Analyst EPS estimate for PTGX
- Consensus EPS estimate$2.49 next reporting period, as of 2026-08-23
Change over time is not available yet: it needs two readings of the same reporting period at least 30 days apart, and we have been recording these estimates since 2026-08-04. An estimate for a DIFFERENT quarter is not a revision, so a reading from before the last report is never compared with one after it.
The consensus estimate for the next reporting period, and how it has moved between readings of that SAME period. A change is measured only between readings estimating one period — when a company reports, the consensus moves to the next quarter and the two numbers are not comparable. Informational only, not a forecast and not advice.
Key risks (from latest filing)
["Significant dependence on collaboration partners for revenue and development funding.","The inherent uncertainty and high risk associated with clinical trial outcomes and regulatory approval processes.","Potential for future dilution of stockholders' equity due to continued issuance of common stock."]
What changed in the latest 10-Q
AI-assisted comparison of PTGX's 10-Q filed 2026-05-05 against the prior one filed 2025-11-06.
Management's Discussion & Analysis (MD&A)
- Added:
- ICOTYDE™ (icotrokinra) was approved in the United States in March 2026 for moderate-to-severe plaque psoriasis (newer filing, 2026-05-05)
- ICOTYDE is the first and only targeted oral peptide that precisely blocks IL-23R (newer filing, 2026-05-05)
- Reference to Audited Consolidated Financial Statements for year ended December 31, 2025 and 10-K filed February 25, 2026 (newer filing, 2026-05-05)
- Risk factors discussion updated to reference 'Part 1. Item 1A of our Annual Report on Form 10-K for the year ended December 31, 2025' (newer filing, 2026-05-05)
- Expanded forward-looking statements risks including 'geopolitical instability, such as the ongoing military conflicts between Russia and Ukraine and in the Middle East and rising tensions between China and Taiwan, elevated and sustained inflation, high oil and other commodity prices' (newer filing, 2026-05-05)
- Added language: 'our ability and that of our collaboration partners to generate sales, income or cash flow' (newer filing, 2026-05-05)
- Company's eligibility for FDA programs or special designations mentioned (newer filing, 2026-05-05)
- Development products and discovery programs organized into three therapeutic areas including metabolic diseases (newer filing, 2026-05-05)
- ICOTYDE in Phase 3 development for additional indications: psoriatic arthritis, ulcerative colitis and Crohn's disease (newer filing, 2026-05-05)
- Removed:
- Reference to Audited Consolidated Financial Statements for year ended December 31, 2024 and 10-K filed February 21, 2025 (older filing, 2025-11-06)
- NDA submitted to the FDA in July 2025 language (older filing, 2025-11-06)
- Second NDA filing expected by the end of 2025 language (older filing, 2025-11-06)
- Icotrokinra referred to as 'first-in-class investigational' product candidate (older filing, 2025-11-06)
- Clinical programs fell into two broad categories: inflammatory/immunomodulatory and hematology/blood disorders (older filing, 2025-11-06)
- Reference to proprietary discovery technology platform (replaced with 'proprietary peptide technology platform') (older filing, 2025-11-06)
- Impact of future outbreaks of disease, epidemics and pandemics (older filing, 2025-11-06)
- Changes in FDA and other government agencies (older filing, 2025-11-06)
- High interest rates referenced as risk factor (older filing, 2025-11-06)
- Prolonged shutdown of U.S. federal government as risk factor (older filing, 2025-11-06)
- Rusfertide referred to as 'first-in-class investigational injectable' (older filing, 2025-11-06)
- Rusfertide Phase 3 development specifics and NDA filing timeline for end of 2025 (older filing, 2025-11-06)
- Takeda co-development and co-commercialization language (older filing, 2025-11-06)
- Rusfertide Breakthrough Therapy designation reference (older filing, 2025-11-06)
- Reworded:
- Company description changed from 'discovery through late-stage development biopharmaceutical company focused on peptide therapeutics' to 'discovery through late-stage development biopharmaceutical company with a proprietary peptide technology platform that enables de novo discovery of peptide therapeutics' (newer filing, 2026-05-05)
- Therapeutic areas renamed from 'inflammatory and immunomodulatory (I&I) diseases and hematology and blood disorders' to 'inflammation and immunology (I&I), hematology and metabolic diseases' (newer filing, 2026-05-05)
- Product reference changed from 'icotrokinra' (generic name focus) to 'ICOTYDE™ (icotrokinra)' (branded name first) (newer filing, 2026-05-05)
- 'Marketing Authorisation Application' changed to 'application' in EMA submission language (newer filing, 2026-05-05)
- Changed 'our ability to generate sales, income or cash flow' to 'our ability and that of our collaboration partners to generate sales, income or cash flow' (newer filing, 2026-05-05)
- Geopolitical risks description expanded from 'ongoing military conflicts, including between Ukraine and Russia and in the Middle East; rising tensions between China and Taiwan' to longer, more detailed version (newer filing, 2026-05-05)
- Notes:
- The newer filing contains a partial/truncated section ending mid-sentence at 'Rusfertide is a first-in-class investigational', limiting full comparison of product pipeline descriptions
- Older filing also appears truncated at the end ('We also have a number of drug discovery and development programs addre'), preventing complete comparison of discovery pipeline details
Risk Factors
The two filings could not be meaningfully compared for this section.
AI-assisted comparison of two SEC filing sections. It describes wording and theme changes only, makes no materiality, legal, or investment judgement, and is not financial advice. Informational only — not financial advice.
Insider activity (SEC Form 4)
0 open-market purchases and 5 open-market sales by insiders in the last 90 days.
- Last 30 days0 buys · 2 sells ($15M) — 1 selling insider
- Last 90 days0 buys · 5 sells ($18M) — 2 selling insiders
- Last 180 days0 buys · 17 sells ($51M) — 6 selling insiders
Activity heuristic: net selling (a transparent product heuristic from the counts above, not a prediction or advice)
Most recent open-market transaction: 2026-08-11. As of 2026-08-24.
View full insider trading history → View SEC Form 3/4/5 filingsAsk about PTGX's insider activity →
Only open-market purchases (SEC code P) and sales (code S) are counted here. Option exercises, vesting/awards, gifts, and shares withheld for taxes are excluded — they are compensation or mechanical, not open-market conviction. Sales may be planned and non-discretionary (e.g. a Rule 10b5-1 plan) and are not necessarily bearish; open-market buying is not a recommendation to buy. Informational only — not financial advice.
Institutional ownership (13F)
5 institutional 13F filers reported holding PTGX as of 2026-03-31 (quarter-end position, filed within 45 days).
- Distinct 13F filers 5
- Reported shares held 15,167,791
- Reported value $1,598,685,198
reported quarterly holdings change (2025-12-31 → 2026-03-31): 1 new, 3 increased, 1 decreased, 1 exited. Change counts cover only managers that filed 13F reports in BOTH quarters, derived between two quarter-end snapshots — not same-day trades; a single manager is never said to have "bought" or "sold".
Institutional holdings are quarter-end long positions reported on SEC Form 13F-HR, filed up to 45 days after the quarter ends — they are delayed, are not real-time trades, exclude short positions and most non-US securities, and are not investment advice. Any increase/decrease is a reported change between two quarterly snapshots, not a same-day purchase or sale. These are quarter-end snapshots from the 13F filings on SEC EDGAR, filed within 45 days — not real-time, and any change is a difference between two quarterly reports, not a same-day trade. Informational only — not financial advice.
Short interest (FINRA)
PTGX had 7,543,109 shares of reported short interest as of the 2026-07-31 FINRA settlement date (delayed, bi-monthly; not real-time).
PTGX had 11.7% of its shares outstanding sold short as of the 2026-07-31 FINRA settlement date (percent of FLOAT would be higher — float is not disclosed in the source). FINRA reported 14.21 days to cover at the same settlement.
- Reported short interest (shares) 7,543,109
- Short interest (% of shares outstanding) 11.7%
- Prior settlement (shares) 8,292,656
- Reported change -9.04%
- Days to cover (reported) 14.21
Reported to FINRA as of the 2026-07-31 settlement date. Short interest is reported to FINRA and published on a delayed, bi-monthly schedule (as of a settlement date, disseminated roughly eight business days later) — it is NOT real-time, does not cover every venue or all US trading, and is not a short-squeeze prediction or investment advice. Days-to-cover is the value FINRA reports; percent of float is not shown because the source file carries no share-count denominator — where a percent appears it is of shares OUTSTANDING, the larger base, and is therefore a floor on percent of float. Informational only — not financial advice.
Competitors & peers
AI-enriched competitor set. Linked names are companies covered by stocks-llm; other named peers are shown for reference only.
Compare PTGX vs…
PROTAGONIST THERAPEUTICS INC is found in…
Frequently asked questions
What does PROTAGONIST THERAPEUTICS INC (PTGX) do?
Protagonist Therapeutics is a biopharmaceutical company focused on the discovery and development of novel peptide-based drugs. The company utilizes a proprietary technology platform to create targeted therapies that address significant unmet medical needs, primarily through oral and injectable formulations.
What sector is PROTAGONIST THERAPEUTICS INC (PTGX) in?
PROTAGONIST THERAPEUTICS INC (PTGX) is classified in the Health Care sector. Its industry is Biotechnology. It trades on NASDAQ.
Who are PROTAGONIST THERAPEUTICS INC's (PTGX) competitors?
Notable peers of PROTAGONIST THERAPEUTICS INC (PTGX) include Johnson & Johnson, Amgen, AbbVie, Eli Lilly and Novartis. This peer set is informational only — not financial advice.
Is PROTAGONIST THERAPEUTICS INC (PTGX) overbought or oversold right now?
PROTAGONIST THERAPEUTICS INC (PTGX) is currently neither overbought nor oversold — its 14-day RSI (a 0–100 momentum gauge) is 63, in the neutral middle (as of 2026-08-21). RSI describes recent price momentum, not a forecast — informational only, not financial advice.
Where does stocks-llm's data on PTGX come from?
Fundamentals and prices come from market data, as of 2026-08-24; company filings and profile facts come from SEC EDGAR. All figures are delayed daily-close data shown with their as-of date — informational only, not financial advice.
Fundamentals: market data, as of 2026-08-24. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-08-21.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date.